Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose subcutaneous gantenerumab in Japanese patients with Alzheimer's disease
jRCT2080221807Phase 1
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gantenerumab in Alzheimer's disease (AD) (4 arms), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080221807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221807.